Pharmacology and toxicology Chapter 36 Antiinflammatory Antipyretic and Analgesic Agents

Overview of Inflammation and Rheumatoid Arthritis (RA)

Inflammation is a fundamental protective response to tissue injury arising from various factors, including physical trauma, noxious chemicals, and microbiological agents. Its primary role is to inactivate or destroy invading organisms, eliminate irritants, and facilitate tissue repair. In typical scenarios, once healing has occurred, the inflammatory process subsides. Nevertheless, inappropriate activation of the immune system can lead to conditions such as rheumatoid arthritis (RA).

Mechanism of Inflammatory Response in RA

In RA, the immune system mistakenly identifies the synovium, which nourishes cartilage and bone, as an external threat, resulting in an inflammatory attack. This involves the activation of white blood cells (WBCs) and T lymphocytes, the latter of which play a critical role in cell-mediated immunity. T lymphocyte activation triggers the recruitment of monocytes and macrophages, which subsequently release proinflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1 into the synovial cavity. These cytokines are responsible for various downstream effects:

  1. Increased Cellular Infiltration: Histamines, kinins, and vasodilatory prostaglandins are released, enhancing the influx of cells into affected regions.

  2. Production of C-Reactive Protein: Hepatocytes increase C-reactive protein production, a marker for inflammation.

  3. Cartilage Degradation: Chondrocytes release proteolytic enzymes leading to cartilage degradation and narrowing of the joint space.

  4. Bone Erosions: Enhanced activity of osteoclasts, which are cells that regulate bone breakdown, results in localized bone erosions and generalized bone demineralization around the joints.

  5. Systemic Manifestations: Some organs, like the heart, may also exhibit systemic manifestations.

B lymphocytes also contribute to the inflammatory process by producing rheumatoid factor and other autoantibodies, which further perpetuate inflammation.

Consequences of RA

As a result of these inflammatory processes, progressive tissue injury occurs, leading to joint damage, erosions, functional disability, considerable pain, and diminished quality of life for affected individuals. The pharmacological management of RA typically employs anti-inflammatory and immunosuppressive medications aimed at modulating or reducing inflammation, ultimately to alleviate pain and halt disease progression.

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Other Agents

Several agents are classified within this pharmacotherapy framework:

  • NSAIDs (e.g., Aspirin, Celecoxib, Diclofenac) act primarily by inhibiting cyclooxygenase enzymes that are pivotal in prostaglandin synthesis. Recognizing the synthesis of prostaglandins is crucial to understanding NSAIDs, as these compounds are involved in mediating pain, inflammation, and fever.

  • Prostaglandins are produced locally by various tissues and act as local mediators. They derive from arachidonic acid, which is released from cell membrane phospholipids through the action of phospholipase A2. The production pathway includes both cyclooxygenase and lipoxygenase pathways that generate various lipid mediators affecting inflammation and immune responses.

Prostaglandins - Local Mediators of Inflammation

Synthesis and Action of Prostaglandins

Prostaglandins, derived from arachidonic acid through the cyclooxygenase pathway, play a strong role in local tissue responses. There are two primary cyclooxygenase isoforms:

  • Cyclooxygenase-1 (COX-1): Responsible for physiological production of prostaglandins, playing a protective role in gastric epithelium and regulating blood flow in kidneys.

  • Cyclooxygenase-2 (COX-2): Inducible during times of inflammation, facilitates the production of prostaglandins at sites of disease.

Prostaglandins exert various effects based on the specific tissue contexts, such as promoting vasodilation, stimulating pain pathways, and influencing the aggregation of platelets.

Therapeutic Uses of Prostaglandins

Agents such as Alprostadil (for erectile dysfunction and maintenance of ductus arteriosus) and Lubiprostone (for chronic constipation) exemplify therapeutic uses of prostaglandins based on their functions, including modulating pain and inflammation, regulating renal function, and controlling gastrointestinal secretions.

Adverse Effects and Clinical Considerations

When NSAIDs are employed, monitoring for gastrointestinal adverse events is critical due to their inhibition of protective prostaglandins in the gastric epithelium. The careful selection of agents based on individual risk factors, alongside the consideration of co-therapy with proton pump inhibitors for at-risk patients, is fundamental to maximizing therapeutic benefits while minimizing adverse events.

Acetaminophen vs NSAIDs

Acetaminophen represents a non-NSAID analgesic that is primarily effective in the central nervous system, presenting a suitable alternative for those at risk of NSAID-related gastrointestinal complications. Unlike NSAIDs, acetaminophen has negligible anti-inflammatory effects and does not inhibit platelet function. While often safe at therapeutic doses, overdose potential warrants caution, particularly in patients with liver disease.

Disease-Modifying Antirheumatic Drugs (DMARDs)

DMARDs are crucial in managing RA to slow disease progression. Methotrexate stands as the primary DMARD, acting as a folic acid antagonist that inhibits cytokine production. Regular monitoring is essential to mitigate any adverse effects during treatment. Alternative DMARDs, including hydroxychloroquine and leflunomide, play complementary roles depending on patient responses.

Biologic Therapies in RA

Biologic agents target specific inflammatory pathways, notably TNF-α inhibitors, which have demonstrated efficacy in reducing inflammation and structural progression in RA. The interplay between traditional DMARDs and biologics underscores the personalized medication approach necessary for managing complex conditions like RA, emphasizing the need for continual assessment of therapeutic efficacy and safety.